In the latest trading session, 0.55 million NRx Pharmaceuticals Inc. (NASDAQ:NRXP) shares changed hands as the company’s beta touched 0.85. With the company’s most recent per share price at $0.26 changed hands at -$0.02 or -8.03% at last look, the market valuation stands at $19.77M. NRXP’s current price is a discount, trading about -492.31% off its 52-week high of $1.54. The share price had its 52-week low at $0.22, which suggests the last value was 15.38% up since then. When we look at NRx Pharmaceuticals Inc.’s average trading volume, we note the 10-day average is 2.38 million shares, with the 3-month average coming to 1.35 million.
Analysts gave the NRx Pharmaceuticals Inc. (NRXP) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended NRXP as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. NRx Pharmaceuticals Inc.’s EPS for the current quarter is expected to be -$0.12.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
NRx Pharmaceuticals Inc. (NASDAQ:NRXP) trade information
Instantly NRXP was in red as seen in intraday trades today. With action 0.04%, the performance over the past five days has been green. The drop to weekly highs of 0.3075 on Friday, 09/15/23 subtracted -8.03% to the stock’s daily price. The company’s shares are showing year-to-date downside of -76.39%, with the 5-day performance at 0.04% in the green. However, in the 30-day time frame, NRx Pharmaceuticals Inc. (NASDAQ:NRXP) is -21.76% down. Looking at the short shares, we see there were 1.44 million shares sold at short interest cover period of 0.66 days.
The consensus price target for the stock as assigned by Wall Street analysts is $3.63, meaning bulls need an upside of 92.84% from its recent market value. According to analyst projections, NRXP’s forecast low is $2.00 with $5.25 as the target high. To hit the forecast high, the stock’s price needs a -1919.23% plunge from its current level, while the stock would need to soar -669.23% for it to hit the projected low.
NRx Pharmaceuticals Inc. (NRXP) estimates and forecasts
Data shows that the NRx Pharmaceuticals Inc. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -63.06% over the past 6 months, a 6.56% in annual growth rate that is considerably lower than the industry average of 9.70%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for NRx Pharmaceuticals Inc. will rise 14.30%, while the growth in revenue is estimated to hit 25.00% for the next quarter.
The 2023 estimates are for NRx Pharmaceuticals Inc. earnings to increase by 91.90%.
NRXP Dividends
NRx Pharmaceuticals Inc. is expected to release its next quarterly earnings report between November 13 and November 17.
NRx Pharmaceuticals Inc. (NASDAQ:NRXP)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 36.03% of NRx Pharmaceuticals Inc. shares while 4.23% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 6.62%. There are 4.23% institutions holding the NRx Pharmaceuticals Inc. stock share, with Armistice Capital, LLC the top institutional holder. As of Jun 29, 2023, the company held 6.90% of the shares, roughly 5.64 million NRXP shares worth $2.73 million.
Vanguard Group Inc holds the second largest percentage of outstanding shares, with 1.81% or 1.48 million shares worth $0.71 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 0.98 million shares estimated at $0.47 million under it, the former controlled 1.20% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.55% of the shares, roughly 0.45 million shares worth around $0.22 million.
